Investor Snapshot: Why This Sector Attracts Capital

Digital therapeutics sits at an unusual intersection: it needs software-company speed and pharma-grade evidence at the same time. That combination is exactly why investors treat it differently from a typical consumer app raise. A seed or Series A pitch for a DTx business has to answer three questions a normal SaaS deck can skip entirely: what is the regulatory pathway (510(k), De Novo, PMA, MHRA, or DiGA), what clinical evidence already exists or is budgeted, and who is the actual payer — a patient, an employer, a health plan, or a pharmaceutical partner.

Funding for early-stage digital therapeutics companies typically comes from four sources: specialist digital-health venture funds, corporate venture arms of pharmaceutical companies looking for a companion-therapy asset, non-dilutive government grants (Innovate UK smart grants in the UK, NIH SBIR/STTR awards and BARDA contracts in the US), and — once a product has FDA clearance or MHRA registration — growth debt secured against contracted payer revenue.

Avvale's bespoke plan service builds this narrative alongside a financial model that reflects the real cost structure of a regulated software product — separating clinical/regulatory spend from engineering spend so investors and grant panels can see exactly where their money goes. See our Bespoke Business Plan service for the full build.

Funding stages in this sector rarely follow a standard SaaS timeline. A pre-seed or friends-and-family round of $150,000–$400,000 typically funds the MVP and an initial single-site pilot study. A seed round of $1M–$4M then funds either the pivotal clinical study or the first 12–18 months of payer contracting, depending on which regulatory path is chosen. Series A, usually $8M–$20M, arrives once a company can show either FDA clearance plus a signed payer contract, or a DiGA permanent listing — investors in this category consistently reward evidence of a real, contracted buyer over raw user-growth metrics, which is the opposite of what most consumer-app investors screen for.

Corporate venture arms deserve a specific mention because they behave differently from traditional VCs in this sector. A pharmaceutical company's venture fund will often accept a lower initial valuation in exchange for a right of first refusal on a future licensing or acquisition deal, because the strategic value of owning a "digital companion" to one of their drugs outweighs the pure financial return calculation a generalist fund would make. A business plan aimed at this specific investor type should quantify how the DTx extends or protects an existing drug's competitive position, not just its standalone unit economics.

Grant panels — Innovate UK, NIH SBIR, and the EU's EIC Accelerator among them — evaluate a plan against a different rubric again: technical novelty, a credible path to a defined health-system outcome, and evidence that the funding genuinely de-risks a step the company could not otherwise afford, rather than simply subsidising a cost a well-funded seed round should already be covering. Plans that reuse the same investor-facing growth narrative unchanged for a grant application typically score poorly, because reviewers are specifically trained to look for public-benefit framing that a straight commercial pitch deck omits. Separating the "why should a private investor fund this" narrative from the "why does this deserve public money" narrative, even when both sit inside the same underlying business plan, measurably improves conversion on both fronts.

The Digital Therapeutics Market in 2026

The global digital therapeutics market was valued at approximately $10.15 billion in 2025 and is forecast to reach $12.45 billion in 2026, according to Fortune Business Insights (2026). Separate modelling from Precedence Research (2025) puts the 2025 figure closer to $9.73 billion, growing to $65.31 billion by 2035 — the spread between estimates reflects how differently research firms define "digital therapeutic" versus the broader digital-health category, so treat any single number as directional, not exact.

North America holds roughly 46.9% of the global market, while Europe accounts for about 23.9% ($2.42B in 2025), per the same Fortune Business Insights dataset. In Germany specifically, the DiGA fast-track reimbursement scheme has driven the number of listed apps from 24 at the end of 2021 to 68 by late 2024, with cumulative reimbursements reaching €234 million by December 2024 — the clearest evidence yet that a defined reimbursement pathway, not clinical quality alone, is what determines commercial traction in this sector.

Behind the headline figures, three structural forces are shaping who wins market share: payer fatigue with unproven wellness apps has raised the evidence bar for anything claiming a therapeutic outcome; large pharmaceutical companies are increasingly licensing or acquiring DTx assets to extend drug patents with "digital companion" products rather than building in-house; and self-insured US employers have become a faster commercial channel than public payers because they can sign a contract in months rather than negotiating a new CMS benefit category that still does not exist for prescription digital therapeutics.

Regionally, adoption is uneven in ways a business plan should address directly rather than gloss over. North America's lead is driven by employer-sponsored health benefits and a large pool of venture capital willing to fund clinical trials; Europe's growth is concentrated in the handful of countries — Germany, Belgium, France — that have built an actual reimbursement pathway, while countries without one see far slower DTx commercialisation regardless of clinical quality. Asia-Pacific is smaller in absolute market size today but is growing fastest in percentage terms, led by Japan's own DTx approval framework (modelled partly on Germany's DiGA) and by South Korea's expanding digital-health reimbursement pilots. A plan that targets international expansion should sequence market entry by reimbursement maturity, not simply by population size or English-language convenience.

One further planning implication: because DTx sits under a medical-device or SaMD regulatory umbrella rather than under a country's general software rules, a company's addressable market is effectively capped by which regulators it has filed with — a US 510(k) clearance does not transfer to the UK, and an MHRA registration does not transfer to Germany. Market-sizing sections that quote a single global TAM figure without breaking it down by jurisdiction-and-clearance-status routinely overstate what is actually reachable in years one through three.

By therapeutic area, four categories account for most of today's commercial activity: mental health and behavioural conditions (insomnia, anxiety, substance-use disorder, ADHD), diabetes and cardiometabolic disease, musculoskeletal and chronic pain, and respiratory conditions. Mental health leads on volume of approved products, partly because software-delivered CBT protocols are comparatively cheap to develop and validate versus a product that needs to integrate with a glucose monitor or a wearable sensor. Diabetes and cardiometabolic DTx, by contrast, tend to command higher per-patient pricing because they typically bundle device integration (continuous glucose monitors, connected scales) with the software layer, which raises both the clinical evidence bar and the achievable price point. A plan should state plainly which of these categories it falls into, since investors and payers benchmark cost, timeline, and pricing expectations against the category norm, not against digital therapeutics as one undifferentiated sector.

Startup Costs & Funding Options

What a digital therapeutics company costs to launch depends entirely on how far you push toward regulated status. A lean MVP aimed at a wellness-adjacent or B2B pilot, with no pivotal clinical trial, typically runs $22,000 to $180,000 (£17,000 to £142,000). A full prescription-DTx build that includes a pivotal clinical study and a formal 510(k) or MHRA submission climbs to $500,000 to $750,000-plus (£394,000 to £590,000-plus), with the clinical study itself usually the single largest cost. FDA data on 510(k) submissions across all device categories shows an average total cost of roughly $31 million from concept to clearance, though the great majority of that figure is driven by higher-risk devices; a narrow, single-indication software submission leaning on an existing predicate can land far below that average.

Cost Breakdown

• MVP engineering, UX & clinical-content build: $40,000–$180,000 (£32K–£142K)
• Regulatory submission (510(k) / UKCA-MHRA): $60,000–$250,000 for a lean first filing (£47K–£197K); full multi-year programmes run far higher
• Pivotal clinical study: $1,000,000–$20,000,000-plus depending on device class and endpoints, with per-patient costs of $14,000–$50,000-plus
• HIPAA/GDPR-compliant hosting, security & SOC 2: $6,000–$59,000/yr (£5K–£46K/yr)
• Reimbursement / health-economics evidence dossier: $25,000–$150,000 (£20K–£118K)
• Commercial launch & payer/provider sales: $15,000–$120,000 (£12K–£94K)

The regulatory submission line deserves the most scrutiny in a first-time founder's budget, because it is the item most often underquoted. A lean single-indication 510(k) that leans on an existing predicate device — the most common and least expensive route — still typically needs a regulatory consultant ($15,000–$60,000 for the filing itself), quality-management-system documentation aligned to ISO 13485 or IEC 62304 for software, and a usability/human-factors study even when no new clinical trial is required. Skipping the human-factors study to save money is one of the most common causes of an FDA "additional information" request that adds three to six months to the review timeline — a delay that is far more expensive than the study itself once payroll burn during the wait is counted.

Funding Routes

In the US, an early-stage DTx company incorporated as a domestic small business can still access SBA 7(a) loans (up to $5M, terms to 25 years) for working capital, hosting, and non-R&D operating costs, though the clinical trial and regulatory spend is more commonly funded by venture capital, corporate pharma partners, or NIH SBIR/STTR grants, which specifically target early-stage health technology with commercial potential. In the UK, the Start Up Loans scheme offers up to £25,000 at 6% fixed interest with free mentoring, and Innovate UK smart grants (typically £25,000–£500,000, non-dilutive) are a common bridge for clinical-evidence generation before a seed round. Our bespoke business plan service includes SBA-compliant and grant-panel-ready financial projections built around whichever funding route fits your stage.

Beyond the one-off launch spend, most founders underestimate ongoing monthly burn. A four-person founding team (clinical/regulatory lead, product/engineering lead, data/security lead, commercial lead) with modest contractor support typically runs $45,000–$95,000 per month (£35,000–£75,000) once salaries, hosting, compliance, and early customer-support costs are included — before any clinical-trial spend, which is usually budgeted and drawn down separately against milestones rather than folded into monthly operating burn. A twelve-month runway at the lower end of that range means a $150,000–$400,000 pre-seed round buys roughly four to nine months before a bridge or seed round is needed, which is why most DTx business plans model a raise timeline in parallel with the regulatory timeline rather than treating them as sequential.

Revenue Model & Profit Margins

Three revenue models dominate this sector. Consumer/B2C subscription DTx (typically for wellness-adjacent, non-prescription products) charges $15–$60 per month directly to patients. B2B2C employer or health-plan licensing charges a per-member-per-month (PMPM) fee, usually $8–$25 PMPM across the full enrolled population regardless of active usage. Prescription digital therapeutics (PDT) billed through payers command the highest per-unit price — historically $400–$1,800 per treatment episode — but require FDA clearance or MHRA/UKCA registration before a single dollar of that revenue can be recognized.

A worked example: a DTx company selling a 12-week PDT programme at $900 per episode to a health plan with 2,400 enrolled patients in year one generates $2.16 million in gross bookings. After clinical operations, patient support, and payer-contracting costs — typically 45–55% of revenue at this scale — net margin lands near 25–30% before amortizing the original clinical-trial investment. Companies further along, with established payer contracts and lower marginal support costs per patient, can push net margin toward the top of the sector's 20–56% range; the wide spread reflects how differently capitalized and how differently reimbursed individual DTx businesses are, even within the same indication.

Additional revenue streams worth planning for include: pharma co-marketing fees (a pharmaceutical partner pays to bundle your DTx alongside their prescription drug), data licensing to research partners (with appropriate patient consent and de-identification), and white-label licensing of the underlying platform to health systems that want their own branded version of the programme.

Contract structure matters as much as headline price. B2B2C employer and payer contracts are typically annual, with renewal tied to a utilisation and outcomes review at month nine to eleven — a plan that shows a credible engagement rate (the share of enrolled members who actually complete the programme) is far more persuasive to a renewing payer than one that only shows enrolment numbers, because payers pay PMPM whether or not a member engages and are increasingly pushing back on low-engagement contracts at renewal. Consumer subscription churn, by contrast, is usually reported monthly and sits meaningfully higher than most B2B2C software — treatment-length programmes (8–16 weeks) that graduate patients out by design should model churn as a feature of the clinical protocol, not purely as a retention failure, which is a distinction reviewers unfamiliar with the sector often miss.

A second worked example illustrates the B2B2C model directly: an employer contract covering 6,000 lives at $12 PMPM generates $864,000 in annual recurring revenue regardless of how many employees actively use the programme in a given month. After clinical operations and customer success costs of roughly 35–45% of revenue at this scale — lower than the PDT example because there is no per-episode clinical billing overhead — net margin on a mature B2B2C book can reach the higher end of the 20–56% range, which is one reason many DTx companies now treat B2B2C as their primary commercial engine and reserve prescription-DTx status for the subset of their pipeline where payer reimbursement per episode genuinely outperforms a PMPM structure.

Comparing the Three DTx Business Models

Most first-time DTx founders default to a consumer subscription model because it is the fastest to launch, then discover mid-way through fundraising that the economics do not support the clinical and regulatory spend they have already committed to. Mapping all three models against each other early avoids that mid-course correction.

Welldoc's BlueStar, one of the earliest FDA-cleared diabetes-management platforms, and Omada Health, which combined chronic-condition coaching with a B2B2C model before its 2024 Nasdaq listing, both illustrate a pattern worth building into your plan: the companies that have scaled durably layered a lower-regulatory-burden B2B2C contract on top of a clinically validated product, rather than betting the entire company on payer reimbursement for a single prescription indication from day one.

Which model belongs in a first business plan depends mostly on runway. A pre-seed team with under twelve months of cash should generally lead with the B2B2C model, since a signed employer or health-plan pilot is achievable inside two to four months and produces the kind of contracted-revenue evidence that makes a seed round far easier to close. A team that has already raised a seed round and has eighteen-plus months of runway can reasonably sequence toward prescription DTx status, using the B2B2C contract as both a revenue bridge and a source of real-world data that strengthens the eventual regulatory submission. Consumer/B2C should be treated as a distribution channel layered on top of one of the other two models rather than as a standalone plan, since direct-to-patient subscription alone rarely funds the clinical evidence generation this sector requires.

A useful diagnostic question when drafting this section: who signs the purchase order, and how long is their typical procurement cycle? A consumer buyer decides in minutes and pays with a credit card; an employer benefits team typically runs a six-to-twelve-month annual enrollment cycle and needs a case built around absenteeism, productivity, or medical-cost offset; a health-plan medical-policy committee can take twelve to eighteen months and will generally not engage seriously without a completed NICE ESF or equivalent health-technology assessment already in hand. Business plans that name the actual buyer and their procurement cycle, rather than describing a generic "target market," are consistently the ones that survive investor and grant-panel diligence.

Regulatory & Legal Requirements

United States

• FDA classification as Software as a Medical Device (SaMD) if any therapeutic claim is made
• 510(k) premarket notification (most common route, relies on a predicate device)
• De Novo classification for novel, low-to-moderate-risk products with no predicate
• PMA (Premarket Approval) for higher-risk, life-sustaining or life-supporting products
• HIPAA compliance for all patient data (hosting, business associate agreements, breach protocols)
• State-level telehealth and prescribing regulations if the DTx is delivered alongside clinician oversight

United Kingdom

• UKCA / MHRA registration as a medical device (software as a medical device pathway)
• Digital Technology Assessment Criteria (DTAC) — covers clinical safety, data protection, technical assurance, interoperability, and accessibility
• NICE Evidence Standards Framework assessment to demonstrate clinical and cost-effectiveness before NHS commissioning
• UK GDPR compliance and an approved Data Protection Impact Assessment
• Local commissioning by one of 43 Integrated Care Systems, since DTx funding in the NHS is not centralised

Germany & Other Jurisdictions

Germany's DiGA ("Digitale Gesundheitsanwendungen") fast-track, run by BfArM, is currently the most predictable reimbursement route in digital health globally. A complete application is reviewed within 90 days; if full clinical evidence is not yet available, manufacturers can secure provisional listing for 12 months (extendable once to 24) while gathering positive-healthcare-effect (pVE) data. Once permanent listing is granted, GKV-SV negotiates a nationwide reimbursement price covering more than 73 million people under Germany's statutory health insurance scheme. Comparable but less mature fast-track frameworks exist in Belgium (mHealthBELGIUM) and France (PECAN), both increasingly referenced by DTx companies planning a phased European rollout that starts in Germany.

Post-Market & Data Protection Obligations

Regulatory work does not end at clearance. FDA-cleared SaMD products are subject to ongoing post-market surveillance obligations, including adverse-event reporting through the Medical Device Reporting (MDR) system and periodic software updates that may themselves require a new 510(k) submission if they materially change the device's function or risk profile — a detail that catches first-time founders off guard when planning a routine app update. On the data side, HIPAA in the US and UK GDPR both require a documented data-flow map, a named data protection officer once processing reaches a certain scale, and — because most DTx products handle special-category health data — a formal Data Protection Impact Assessment before launch, not after a regulator asks for one. Budgeting legal and compliance counsel as an ongoing line item, not a one-time launch cost, is one of the clearest signals a business plan is written by someone who understands this sector rather than a generic software founder.

Five Mistakes That Sink DTx Startups

Digital therapeutics has a shorter track record than most sectors we write plans for, which makes the failure patterns unusually consistent and unusually instructive. Here are the six we see most often when reviewing early-stage plans, ordered roughly by how early in the company's life they tend to do damage — the first three are strategic errors made before a product ever reaches a patient, the last three are operational errors made after launch.

• Designing the clinical trial after the product, not before it. Retrofitting a randomized controlled trial onto an MVP that was never built to capture the right endpoints adds months and often forces a costly rebuild.
• Chasing FDA clearance before securing a single committed payer or employer pilot. Pear Therapeutics is the industry's clearest cautionary tale here: despite more than 40 supporting studies and FDA-cleared substance-use-disorder products, the company filed for Chapter 11 bankruptcy in April 2023 after spending roughly $150 million building a broad pipeline ahead of payer validation. Clearance alone does not create demand.
• Pricing as a consumer subscription when the real buyer is a self-insured employer or health plan. A $19.99/month app price signals "wellness," not "clinical intervention," and undercuts the PMPM or per-episode pricing a B2B2C or PDT buyer expects to pay.
• Ignoring EHR interoperability (HL7 FHIR) until late in development. Health-system procurement teams routinely stall a sale by 6–12 months if a product cannot integrate with Epic, Cerner, or a payer's care-management platform.
• Underestimating post-launch clinical operations headcount. The coaching, adherence-monitoring, and patient-support staff needed to hit the outcomes promised in a regulatory submission are frequently missing from year-one hiring plans, which then undermines the real-world evidence needed for permanent DiGA listing or ongoing payer contracts.
• Treating a software update as routine once a product is FDA-cleared. Founders coming from a general SaaS background are used to shipping continuously; a materially significant update to a cleared SaMD product can trigger a new 510(k) filing, and teams that skip that check risk having their clearance invalidated mid-contract with a payer.

None of these mistakes are unique to digital therapeutics individually — under-resourcing customer success, retrofitting evidence generation, and mispricing for the actual buyer are common startup errors in any regulated or B2B2C sector. What is specific to this sector is how expensive each mistake becomes once compounded by a multi-hundred-thousand-dollar clinical study or a multi-year payer contract: a pricing error discovered after a twelve-month NHS Integrated Care System commissioning cycle cannot simply be corrected with an app-store price update the way it could be in most consumer software businesses.

Sample Business Plan Preview

Here's an extract from a real digital therapeutics business plan written by our team — so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry, and written so a clinical co-founder and a commercial co-founder can each recognise their own contribution in the final document:

• Executive Summary — Your business at a glance, written to hook investors in 60 seconds
• Company Overview — Legal structure, ownership, location, and founding story
• Industry Analysis — Market size, growth trends, and the regulatory pathway relevant to your product
• Customer Analysis — Target patient population, buyer (patient vs. payer vs. employer), and adoption drivers
• Competitor Analysis — Direct DTx competitors and adjacent digital-health substitutes, plus your differentiation strategy
• Marketing Plan — Channels, messaging, and customer or payer acquisition strategy
• Operations Plan — Clinical operations, data security, and key regulatory milestones
• Management Team — Founder bios, clinical advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements — structured to separate clinical/regulatory spend from engineering and commercial spend, which investors and grant reviewers in this sector expect to see itemised.

Because this sector spans everything from a pre-clearance MVP to a post-DiGA commercial-stage business, we tailor the depth of the industry-analysis and financial-forecast sections to your actual stage rather than shipping a single generic version. A pre-seed plan leans heavily on the regulatory-pathway narrative and a bottom-up cost model; a plan for a company that already has a signed employer or payer contract leans instead on unit economics, contract-renewal assumptions, and a credible path to the next funding milestone. Tell us your stage when you order the Research + Content or Bespoke package and we'll weight the sections accordingly.

If your product is closer to a pure software analytics play with no FDA involvement at all, our SaaS Business Plan Template guide may be a better structural fit. If you're building physical or hardware-adjacent medical devices rather than pure software, see our Medical Device Development Business Plan Template for the hardware-specific FDA pathways.

Frequently Asked Questions